Evaxion Biotech
Pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 4481 % | - | - | 1425 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (29353 %) | (415 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (30308 %) | (316 %) | - | (281 %) | 67 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 16323 % | 313 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Evaxion Biotech is a pioneering company in the field of AI-driven immunology, focusing on decoding the human immune system to discover and develop novel immunotherapies. The company leverages its proprietary AI platforms—PIONEER™, EDEN™, and RAVEN™—to translate vast amounts of biological data into actionable insights. These platforms enable the rapid and cost-effective design of new treatments for cancer and infectious diseases.
Evaxion Biotech operates in the biotechnology sector, serving pharmaceutical companies, healthcare providers, and research institutions. Its business model revolves around the development and commercialization of immunotherapies, which are treatments that use the body's immune system to fight diseases. The company generates revenue through partnerships, licensing agreements, and direct sales of its therapeutic products.
With a team of highly skilled bioinformaticians, scientists, and executives, Evaxion Biotech is committed to advancing global health. The company is currently engaged in clinical collaborations to evaluate its lead product candidates, including a partnership to test a melanoma treatment in combination with pembrolizumab.
Keywords: AI-driven, immunology, immunotherapies, cancer, infectious diseases, biotechnology, PIONEER™, EDEN™, RAVEN™, clinical collaboration.